Stocks · News reference
AnaptysBio Q2 Adj. EPS $(0.11) Beats $(0.46) Estimate, Sales $27.488M Beat $21.675M Estimate
AnaptysBio (NASDAQ:ANAB) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.46) by 76.09 percent. This is a 91.79 percent increase over losses of $(1.34) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
HC Wainwright & Co. Reiterates Buy on AnaptysBio, Maintains $95 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates AnaptysBio (NASDAQ:ANAB) with a Buy and maintains $95 price target.
Leerink Partners Maintains Outperform on AnaptysBio, Lowers Price Target to $81
Leerink Partners analyst David Risinger maintains AnaptysBio (NASDAQ:ANAB) with a Outperform and lowers the price target from $90 to $81.
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates
AnaptysBio (ANAB) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.46 loss, with a 76% earnings surprise. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The Medical - Biomedical and Genetics industry ranks in the bottom 32% of sectors. Nurix Therapeutics (NRIX) is expected to report results with a projected loss of $0.56 per share but with significant revenue growth of 1665.8% year-over-year.